Skip to main
ASTH

ASTH Stock Forecast & Price Target

ASTH Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Astrana Health is a leading company in the integrated population health management industry, with a strong focus on delivering high-quality, cost-effective medical care through their Care Partners segment. The company's use of AI technology and acquisition of Prospect Medical are expected to contribute to revenue growth and risk-based contracts, but they face competition and uncertainties in Medicare payments. Despite these challenges, Astrana Health remains on track to achieve their goals, with slightly above and below average scores for Medicare fee-for-service and Medicare Advantage, and potential risks related to value-based care, contract renewals, healthcare utilization, and accounting issues.

Bears say

Astrana Health is facing several market-level and company-specific risks that could hinder its growth potential. These include intense competition from larger value-based health management companies in the Medicare Advantage space, pressure from smaller and recent entrants, the financial health of its payer partners, and potential changes made by CMS to MA regarding payments. Moreover, Astrana's reliance on the Medicare market and potential declines in membership could also negatively impact the company's revenue and profitability. Additionally, the company's high debt load may limit its ability to invest in new opportunities and expand the business. Despite its strong track-record in delivering high-quality care and generating cost-savings, these risks could impact Astrana's growth and make it a less compelling option for physicians and payers.

ASTH has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Astrana Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Astrana Health Inc (ASTH) Forecast

Analysts have given ASTH a Strong Buy based on their latest research and market trends.

According to 7 analysts, ASTH has a Strong Buy consensus rating as of Jul 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Astrana Health Inc (ASTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.